Business Wire

SAMSUNG-ELECTRONICS

25.6.2024 12:14:26 CEST | Business Wire | Press release

Share
Samsung Electronics Announces Successful Building of Industry-First CXL Infrastructure Certified by Red Hat

Samsung Electronics Co., Ltd., the world leader in advanced memory technology, today announced that for the first time in the industry, it has successfully built a Compute Express Link™ (CXL™) infrastructure certified by Red Hat, the world’s leading provider of open source solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625016573/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Samsung Electronics Announces Successful Building of Industry-First CXL Infrastructure Certified by Red Hat (Photo: Business Wire)

Elements that configure servers, from CXL-related products to software, can now be directly verified at the Samsung Memory Research Center (SMRC) located in Hwaseong, South Korea. Once CXL products are verified by Samsung, they can immediately be requested for product registration to Red Hat, enabling faster product development.

Marking its first achievement through the infrastructure, Samsung has successfully verified its CMM-D product for the first time in industry this month. The company can also provide tailored solutions to customers by optimizing products at earlier development stages.

“We’re very pleased that our partnership with Red Hat is able to deliver CXL memory products with enhanced reliability to our customers,” said Taeksang Song, Vice President and Head of the New DRAM Solution Development Team at Samsung Electronics. “Through our continued collaboration spanning software and hardware, we will remain at the forefront of developing innovative memory solutions as well as the CXL ecosystem.”

Kyeong Sang Kim, Red Hat Korea GM said, “The optimization of Samsung’s hardware for Red Hat’s software underscores the value of open source technology as an imperative when it comes to expanding next generation memory solutions such as CMM-D. We look forward to continuing our collaboration with Samsung to further extend CXL solutions to the market.”

Following the successful CXL memory verification by Red Hat for the first time in the industry last December, Samsung has also been certified for datacenter SSD products. Customers using Red Hat-certified products can build high-performance systems by receiving world-class Linux support, complementing the stable hardware operation of Samsung.

Samsung and Red Hat have also been working closely together in various areas, including product certification for both hardware and software, enriching the next-generation CXL ecosystem.

At the Red Hat Summit held in Denver, Colorado, in May, Samsung demonstrated its CMM-D1 embedded in Red Hat Enterprise Linux 9.3, which enhances the performance of Deep Learning Recommendation Models (DLRM).

The demo utilized the Scalable Memory Development Kit's (SMDK) Memory Interleaving software technology, highlighting improved memory access performance. SMDK-equipped CMM-D allows customers to build high-performance AI models, without having to make significant investments, by accelerating the data processing, AI learning and inferencing speeds.

Through their strong partnership, Samsung and Red Hat aim to provide customer solutions suitable for a wide range of user systems while introducing new technology standards to an array of partners and customers and expanding the CXL memory ecosystem.

1 CMM-D is Samsung’s CXL Memory Module DRAM, a DRAM solution based on the PCIe interface that supports the CXL protocol.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, home appliances, network systems, and memory, system LSI, foundry and LED solutions, and delivering a seamless connected experience through its SmartThings ecosystem and open collaboration with partners. For the latest news, please visit the Samsung Newsroom at news.samsung.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625016573/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors9.9.2026 15:45:00 CEST | Press release

- Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach – Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function of coagulation Factor VIII, which is deficient in hemophilia A. Provided improved convenience through prolonged activity and subcutaneous administration, and provided a treatment option regardless of factor VIII inhibitors, thereby helping address unmet medical needs in hemophilia A. First time since the establishment of the Lasker Foundation in 1945 that three Japanese researchers have received the award simultaneously. Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that Dr. Kunihiro Hattori (former Senior Fellow of Chugai), Dr. Takehisa Kitazawa (Deputy Head of Research Division, Chugai), and Dr. Tomoyuki Igawa (Head of Research Division, Chugai), who led the creation of Hemlibra (emicizumab), a treatment for hemophilia A, have been aw

AMCS Appoints Richard Humphrey as Chief Product and Technology Officer9.9.2026 15:00:00 CEST | Press release

Industrial software executive to lead global product strategy and accelerate AI innovation AMCS, a leading technology provider for the waste and recycling industry, today announced the appointment of Richard Humphrey as Chief Product and Technology Officer. Based in Boston, Humphrey will lead the company’s global product organisation. Humphrey brings more than 25 years of experience developing software for construction and other complex industrial environments. He joins AMCS as the company deepens its focus on waste and recycling and expands the role of AI across its platform. Most recently, Humphrey served as Chief Product and Technology Officer at Contruent, where he led product strategy for a construction cost-management platform used on major capital programmes. He previously held vice president roles at Bentley Systems and B2W Software. Earlier in his career, he spent more than a decade at Autodesk, where he led its Civil Design and Construction software business as Senior Directo

BBH Launches a New Technology Business, Braid, Solving for Intelligent Data Transformation9.9.2026 14:45:00 CEST | Press release

Braid’s agentic AI platform is purpose-built for financial services firms who need to transform, connect, and manage their data with confidence Brown Brothers Harriman (BBH) today announced the launch of a new technology affiliate, Braid LLC, focused on solving enterprise data transformation for financial services. Braid offers an AI-native data transformation platform that gives firms a scale solution to transform, connect, and manage their data with confidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909294398/en/ Braid empowers teams to build, automate, and oversee reliable production-grade data transformations in a fraction of the time typically required today. Instead of requiring engineers to build data automations, Braid allows business users to describe their needs in natural language that AI agents use to build intelligent data transformations that are transparent and fully auditable. Braid’s enterprise-gr

LTM Collaborates with IBM and Red Hat on Lightwell to Advance AI-Driven Open-Source Software Remediation9.9.2026 14:30:00 CEST | Press release

Strengthens software supply chains by helping enterprises transform vulnerability discovery into scalable remediation outcomes LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation. As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications. Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell aims to help organizations address securi

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life9.9.2026 14:24:00 CEST | Press release

Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-86

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye